Neuro

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

NANJING, China, Sept. 5, 2024 /PRNewswire/ — On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation…

New Research Published in Nature Medicine Highlights the Benefit of Anti-Blood Clot Medications to Prevent Stroke Among Patients Undergoing Non-Cardiac Surgery

Risk Predication Tool, Developed by Anesthesiologists at Montefiore Health System and Albert Einstein College Medicine, May Reduce Adverse Outcomes BRONX, N.Y., Aug. 23, 2024 /PRNewswire/ — A new computational risk assessment prediction tool developed by anesthesiologists at Montefiore…

Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke

Gosselies (Belgium), August 21, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies to prevent and treat thrombotic and inflammatory diseases, announces today that the DMC reviewed the data from the first 8 patients in a planned review of the ongoing BIRCH Phase 2a trial of BIOX-101 to prevent secondary damage after intracerebral hemorrhagic stroke (ICH).

MemorialCare’s Long Beach Medical Center and Saddleback Medical Center Nationally Recognized by the American Heart Association with Get with the Guidelines Gold Plus Awards

FOUNTAIN VALLEY, Calif., Aug. 20, 2024 /PRNewswire/ — MemorialCare’s Long Beach Medical Center and Saddleback Medical Center received the American Heart Association’s Get With The Guidelines® – Stroke Gold Plus quality achievement awards. Long Beach Medical Center also received the Get…

Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the GREEN Study

July 26, 2024 02:00 AM Eastern Daylight Time PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announces the conclusions of the futility analysis of the phase 2/3 GREEN study evaluating glenzocimab as an adjunct […]

Imperative Care Announces Clinical Data from the Pivotal Imperative Trial Evaluating the Zoom Reperfusion System for the Treatment of Ischemic Stroke

Late-Breaking Data Presented at SNIS Suggest Lower Rates of Rescue Therapy Than Prior Thrombectomy Trials; Rapid Reperfusion Time; High Rates of Reperfusion July 24, 2024 01:30 PM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that late-breaking data from the Imperative Trial were presented at the Society of […]